{"entity":{"id":"nct07288203","kind":"trial","name":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma","aka":[],"tldr":"A phase 2 trial of Lifileucel in melanoma and skin cancer, run by Iovance Biotherapeutics, Inc., active and no longer recruiting.","summary":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma is a phase 2 interventional study registered as NCT07288203 by Iovance Biotherapeutics, Inc., with 100 participants planned, started 2025-11-28 and due to reach its primary completion in 2032-12. Interventions recorded: Lifileucel. Conditions listed: Melanoma (Skin Cancer), Unresectable Melanoma, Metastatic Melanoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07288203","url":"https://clinicaltrials.gov/study/NCT07288203"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma","skin-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["lifileucel"],"companies":["iovance"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07288203","phase":"2","setting":"A Phase 2, Multicenter, Open-label Study of Lifileucel (Tumor-infiltrating Lymphocytes [TIL]) in Participants With Previously Treated Advanced Melanoma","sponsor":"Iovance Biotherapeutics, Inc.","enrolled":100,"outcomes":[]},"route":"/trials/nct07288203/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/"}],"drug":[{"id":"lifileucel","kind":"drug","name":"Lifileucel","route":"/drugs/lifileucel/"}],"company":[{"id":"iovance","kind":"company","name":"Iovance Biotherapeutics","route":"/companies/iovance/"}]}}